ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021

ADMA Biologics will announce its Q3 2021 financial results on November 10, 2021, after U.S. markets close.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

ADMA Biologics will announce its Q3 2021 financial results on November 10, 2021, after U.S. markets close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide company updates. ADMA, focused on specialty plasma-derived biologics, has three FDA-approved products: ASCENIV™, BIVIGAM®, and NABI-HB®, aimed at treating immunodeficient patients. The company manufactures these products at its FDA-licensed facility in Florida.

Positive

ADMA has three FDA-approved plasma-derived biologics.
Company's focus on niche patient populations offers potential for growth.

Negative

None.

Argus Session date unavailable

+5.67% session move Open Argus

Details

News Market Reaction – ADMA

The recorded move for ADMA in the trading session of this news was +5.67%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/03/2021 - 07:00 AM

Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the third quarter ended September 30, 2021 on Wednesday, November 10, 2021 after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.

To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer to conference ID 4459844. A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

COMPANY CONTACT:
Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will ADMA report its Q3 2021 financial results?

ADMA will report its Q3 2021 financial results on November 10, 2021.

What time is the ADMA conference call scheduled?

The ADMA conference call is scheduled for 4:30 p.m. ET on November 10, 2021.

What products does ADMA Biologics manufacture?

ADMA manufactures ASCENIV™, BIVIGAM®, and NABI-HB®.

Where does ADMA produce its biologics?

ADMA produces its biologics at its FDA-licensed facility in Boca Raton, Florida.

How can investors access the ADMA conference call?

Investors can dial (855) 884-8773 or (615) 622-8043 to access the call.

ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021